Objective: To determine whether analysis of sequence variation in reverse transcriptase at baseline can explain differences in response to combination antiretroviral therapy. Methods: Amino acid sequences of reverse transcriptase obtained from baseline isolates from 55 patients included in a trial of zidovudine and didanosine versus zidovudine/didanosine/nevirapine (ACTG241) were analysed. Simple and multiple linear regression were used to determine the relationship between numbers and identity of mutations at baseline and virological response after 8 and 48 weeks. Results: Numbers of baseline zidovudine resistance mutations were predictive of short-term response (week 8). Amino acid identity at position 215 explained . 20% of the variation in response at week 8, but less at week 48. Multiple regression identi®ed the combinations: 215 44 and 41 202, each of which explained about 30% of the variation in week 8 response. A model incorporating amino acids 214 215 60 202 baseline viral load explained . 40% of the variation in response at week 48. Unexpectedly, the mutant combination 60I 215Y/F responded threefold better than 60V 215Y/F over 48 weeks. Conclusions: Use of clinical data to analyse virological response to combination therapy has revealed effects of baseline amino acid mutations at sites not previously identi®ed as being important in antiretroviral resistance. Predictors of long-term responses were different from those involved in the short term and may require more complex analysis.
Introduction
Mutations in the HIV-1 pol gene that contribute to drug resistance have been identi®ed for all of the currently available antiretroviral agents by their frequent appearance under drug pressure in culture and in patients failing therapy. High level resistance may be conferred by a single amino acid substitution [1±4] or, particularly in the case of zidovudine (ZDV) and protease inhibitors, may require the stepwise accumulation of a number of mutations of incremental effect [5±7] . Treatment with more than one drug, sequentially or in combination, can lead to the development of multiply resistant strains [8, 9] . As the emergence of drug resistant mutants has been shown to correlate with resurgence in plasma RNA levels [2, 4, 10] , information on resistance mutations at the outset of therapy might predict virological, and ultimately clinical, response, as declines in viral load during antiretroviral therapy are associated with a decreased risk of disease progression [11±14] . It has recently been shown that short-term virological response to salvage therapy is better predicted by the number of mutations associated with resistance to antiretroviral agents present at baseline than by drug history, viral load or CD4 cell count [15] ; high level ZDV resistance, and ZDV resistance mutations at positions 215 and 41 have been found to be predictive of disease progression during treatment with ZDV or didanosine (ddI) [16±18] .
The properties of speci®c mutations can be ascertained in vitro by the change in drug sensitivity conferred by the introduction of the mutation(s) to a de®ned genetic background. In this way, the additive and synergistic contributions of individual mutations to the development of resistance have been determined [1, 3, 5, 6, 19] . Antagonism between mutations, such as the suppression by M184V or Y181C of the ZDV resistance conferred by T215Y, has also been detected [1±3,19] . However, alternative resistance pro®les arise in different patients which vary either because of the effects of pre-existing polymorphisms and resistance mutations [9,20±22] or as a result of random events in the evolution of the viral population [23, 24] . As more patients are exposed to greater numbers of drugs, the complexity of the patterns of mutations seen in clinical isolates increases making it dif®cult to identify the best predictors of the outcome of combination therapies.
We have analysed the nucleotide sequences of HIV isolates obtained from patients enrolled in a randomized, double-blind, placebo-controlled trial of ZDV/ ddI versus ZDV/ddI/nevirapine (ACTG241 [25] ). A total of 398 ZDV-experienced patients with CD4 cell counts < 0.35 3 10 6 /l completed the trial, and patients receiving the triple combination showed a 0.25 log 10 lower mean plasma viral load, and 18% higher mean CD4 cell count, after 48 weeks than patients receiving dual therapy [25] . Sequences of reverse transcriptase (RT) were obtained from a selected subset of patients, at weeks 0, 8 and 48 (Hanna, Johnson, Kuritzkes, Richman, Leigh Brown, Savara, Hazelwood, D'Aquila, unpublished data). We have applied simple and multiple linear regression analysis to data available from 55 patients and have found that a substantial proportion of the variation in the ratio of the baseline viral load to viral load at week 8 and week 48 (`virological response') can be explained on the basis of sequence variation present at baseline. This approach has shown that whereas some sites identi®ed from in vitro studies are important, others not previously known to be associated with antiretroviral resistance play a signi®cant role in the clinical context.
Methods
Sequence analysis A 1.2kb DNA fragment of HIV-1 pol was ampli®ed by PCR from lysates of infected cultured cells and sequenced using high-density oligonucleotide arrays (Affymetrix, Santa Clara, California, USA), as described previously [26] . The baseline nucleotide sequences of the RT coding region (codons 1±242) from 55 patients were aligned using the Genetic Data Environment multiple sequence editor and all subsequent analyses were performed on inferred amino acid sequences of RT. Amino acids at each site were classi®ed as mutant or non-mutant relative to the consensus for clade B [27] . Different mutant amino acids at the same site, such as 215Y and 215F, were combined.
Viral quanti®cation
HIV plasma viral RNA was quanti®ed with the Amplicor Monitor assay (Roche Molecular Systems, Branchburg, New Jersey, USA), with a cut-off of 200 copies/ml. Undetectable viral loads were given a value of 200 for calculation of virological response. Virological response was de®ned as the ratio of the baseline viral load to the viral load at week 8 or week 48. For statistical analysis these values were normalized by log 10 transformation.
Statistics
Statistical analyses were performed using Microsoft Excel, SPSS for Windows version 6.1.3 and Minitab for Windows version 11.2. Multiple regression models were identi®ed using stepwise and best subsets approaches. For stepwise regression, the criteria for entry and removal were set as P in 0.05 and P out 0.10. Best subsets regression identi®ed combinations of variables with the highest value of R 2 for each number of parameters (1±20) in the model. As the number of free predictors in the model is limited to 20, it was necessary to repeat the best subsets procedure: starting with the 20 variables with the highest value of R 2 in bivariate regression, the last ®ve (or six if including RNA) variables to enter any multiple regression model were repeatedly removed until all the models containing up to at least four (®ve) parameters (the maximum number for which all variables were likely to be signi®cant, as suggested by stepwise regression) were constant. In order to compare models with different numbers of parameters, R 2 values for multiple regression models were adjusted for the number of variables. The adjusted value, adjR 2 , is equal to R 2 ± { p(1 ± R 2 )/(n ± p ± 1)}, where p is the number of independent variables in the equation. The numbers in each treatment arm were too small to analyse separately, but there was no difference in mean virological response between arms in the patients used in this analysis.
Results

Bivariate regression
Sequences of the RT coding region between amino acids 1 and 241 were obtained from 55 patients. Substantial diversity was detected in the amino acid sequences obtained from baseline samples: 25 amino acid sites showed a variant in six or more patients. These included six sites associated with ZDV resistance (41, 67, 70, 210, 215 and 219), but none speci®cally associated with ddI or nevirapine resistance. At week 48, 33 sites were classi®ed as variable, including 103, 106, 181 and 190 which are associated with resistance to nevirapine. For 52 patients for whom week 8 viral loads were available, and 47 patients with week 48 data, bivariate regression was performed of virological response at each time point on normalized baseline viral load (`baseline RNA'). Although baseline viral load was positively correlated with week 48 viral load, (r 0.90, P , 0.001) the measure of virologiccl response adopted was not correlated with baseline RNA at either time-point.
The number of mutations present at baseline and the number of ZDV-associated mutations was analysed in relation to virological response. The total number of mutations present at week 0 in each patient at the 25 variable sites ranged from 1 to 15 (mean, 6.5). A greater number of mutations at baseline was signi®-cantly associated with a poorer response at week 8 (R 2 0.08, P 0.0410). When only the number of mutations at the six sites associated with ZDV resistance [5, 28] (mean, 2.5; range, 0±4) were considered, the signi®cance was increased (R 2 0.19, P 0.0012). However, numbers of mutations were not predictive of response at week 48 using either approach (Table 1) .
Amino acid identity at baseline at ®ve sites was found to have a signi®cant individual effect on virological response at week 8 ( Table 2) . Three of these, 41, 210 and 215, are well known to have a major impact on susceptibility to ZDV. Two other sites which had signi®cant individual effects were amino acid (aa) 44 and aa 39, where variant amino acids were observed in seven and six individuals respectively. In contrast, virological response at week 48 (Table 2) was affected by baseline amino acids at 214 and 215, and weakly by aa 196 and 200, thus only aa 215 is common to both sets.
The median values for the viral load ratios for patients with mutant versus those with wild-type amino acids at baseline differ by two-to sixfold ( Table 2) . As expected, mutations at aa 215, 41 and 210 were associated with a poorer response to therapy (lower ratio), and patients with mutations at positions 44 and 39 also responded less well. Mutations in baseline sequences at aa 214, 196 and 200 were associated with a stronger response to therapy at week 48 (higher ratio, Table 2 ).
Multiple regression
Stepwise multiple regression identi®ed aa 215 and 44 on the basis of virological response at week 8 (adjR 2 0.291, P 0.0001). The same procedure selected a model involving four sites at week 48: aa 214, 215, 60 and 202 (adjR 2 0.35; P 0.0002).
Best subsets regression was used to identify other combinations of sites which together explained the highest proportion of the variance in virological response. For response at week 8, this indicated that aa 41 and 202 together explained slightly more of the variation in response than did aa 215 and 44. Allowing three parameters included aa 39 with 41 and 202, raising the adjR 2 from 0.311 (Table 3) to 0.347; the second greatest addition was with aa 44 (adjR 2 0.342 P , 0.0001). As the number of variables allowed in the model is increased, aa 215 and 200 (four or more variables), and baseline RNA (six or more variables) are included (Table 3) . However, the increment in adjR 2 is small, to 0.37 with four variables and just 0.38 with ®ve or more.
There was no signi®cant difference in week 8 response between baseline 215Y and 215F (P 0.60, n 38). However, mutants at aa 41 always occurred in conjunction with 215Y (not 215F) (Hannah, Johnson, Kurtizkes et al., unpublished data). Amongst the patients with the wild-type residue at aa 41 at baseline, those with 215F had a signi®cantly worse response at week 8 than those with 215Y (P 0.05, n 14). Week 48 response did not differ signi®cantly between 215F and 215Y, with or without allowance for aa 41 genotype (P 0.20, n 13; P 0.45, n 35 respectively).
For virological response at week 48, baseline RNA became signi®cant in the presence of a mutation at aa 215, and signi®cantly (P 0.002) increased the value of R 2 of the four-site model (four sites and baseline RNA adjR 2 0.478; P , 0.001; Table 4 ), while also fullilling the stepwise criteria. Amino acids 200 and 214 were identi®ed in the bivariate analysis, but aa 60 is signi®cant only in a model which includes aa 215 as all 10 cases of 60I are found with 215Y/F. Sites 200 and 202 add a similar increment to R 2 , in a four-site model but, unlike aa 200, 202 was signi®cant only when 214 and 60 were included.
From the viral load ratios it appears that the presence of 60I substantially reduces the negative effects of 215Y/F. The ratio for aa 215 mutants overall is 0.74 whereas that for 60I 215Y/F is 1.65. The ratio for 60V, 215Y/F patients (n 25) is 0.47, thus the presence of 60I has an approximately threefold effect on the viral load ratio after 48 weeks. Together with individuals who were wild-type at aa 215 at baseline, three groups can be identi®ed with decreasing mean response at week 48: 60V 215T, 60I 215Y/F, 60V 215Y/F (Fig. 1) . Mean baseline RNA is lower for the 215T class than for the 215Y/F classes, as described previously [29] . In the latter group, larger changes in viral load are associated with lower baseline values: patients with 60V 215Y/F make up the majority of those with low baseline RNA and poor response (Fig.  1 ).
In contrast with V60I, mutant amino acids at position 202 are associated with a poorer response. Thus, the four-site regression model indicates that variation at three amino acid sites which are not strongly associated with resistance can be combined with aa 215 in explaining the overall response on the trial. However, the inclusion of aa 60 and 202 in the model is unexpected on the basis of the relatively small effect on their own.
Associations between amino acid sites
The novel sites identi®ed by the regression analysis (aa 60, 202, 196, 44 and 39) were tested for association with known resistance mutations and other variable sites. Signi®cant associations were found between aa 60 and 215, referred to above (one-tailed P 0.035, Fisher's exact test) and between aa 202 and both 219 and 41 (one-tailed P 0.01 and 0.03, respectively). Although mutations at aa 41 and 219 are important for ZDV resistance, neither increased the R 2 value of the Table 3 . Multiple regression of amino acid variation in baseline sequences on virological response at week 8. The model with the highest value of adjR 2 is shown for each number of amino acid sites included, except for the model identi®ed by stepwise regression indicated by Ã . 
Number of variables Amino acids AdjR
Discussion
While the likely outcome of ZDV monotherapy can be predicted on the basis of the presence or absence of mutations at aa 215 and 41 [5] , in combination therapy it is not yet clear what information is required to predict a response. We have analysed whether baseline sequences can be informative in predicting outcome to therapy, using two approaches. We have tested the predictive capacity of genotype at individual aa sites, including 215, by a simple bivariate regression, and secondly, we have applied multiple regression methods to the variation in the baseline sequences. Lorenzi et al.
found baseline numbers of RT and protease inhibitor resistance mutations to be predictive of virological response following 4±12 weeks of salvage therapy including nel®navir [15] . We have found that, although numbers of ZDV resistance mutations are predictive of response after 8 weeks, they do not predict long-term response to combination therapy, for which the baseline amino acid identity at key sites is more important. Numbers of mutations might, however, retain their predictive capacity during long-term therapy with protease inhibitors, resistance to which is characterized by overlapping pro®les of multiple mutations. It is particularly interesting to consider the interaction between position 60 and 215 in this case as aa 60 has not been identi®ed previously as being associated with either nucleoside or non-nucleoside RT inhibitor resistance. From these results it is clear that despite having a small effect when considered on its own, it has a substantial in¯uence on outcome in the presence of 215Y/F, reducing the negative effect of mutants at 215 on the response to long-term therapy. Residue 60I is a common polymorphism in some subtypes [27] and has been recorded by Najera et al. in one out of 25 antiretroviral-naive patients, where it occurred with wild-type 215T, and in one out of 35 nucleosideexperienced patients (with 215Y) [31] . It has also been seen to arise on a 215Y background during prolonged ZDV therapy, but this was not accompanied by a quanti®able change in in vitro resistance to ZDV [33] . The appearance of 60I solely in conjunction with 215 mutants in ACTG241 patients suggests that it confers some immediate ®tness advantage in the presence of nucleoside inhibitors, but that in the long term it clearly reduces the virus' ability to respond to continuing therapy. In view of the increasing ease of obtaining genotypic data from HIV sequences, the ability to predict responses to antiretroviral therapy on the basis of information on sequence variation at baseline is of direct clinical relevance. We have shown that analysis of clinical data using multiple regression can identify associations of speci®c amino acid sites with response to combination therapy. In an analysis based on viral isolates we have found some sites to be important which have not been identi®ed in vitro as having a role in antiretroviral resistance. It is likely that a similar analysis of sequences obtained directly from patients' plasma would be even more powerful, because of the possibility of loss of viral variants during culture in the absence of drug. We have also shown that the prediction of short-term and longer term responses may involve different parameters. While this analysis does not allow any direct inference regarding mechanisms, all of these conclusions can be tested directly by investigation of independent datasets.
